BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35419413)

  • 1. Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma.
    Xie L; Dai R; Wang X; Xie G; Gao Z; Xu X
    Front Mol Biosci; 2022; 9():806780. PubMed ID: 35419413
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
    Li Y; Gu J; Xu F; Zhu Q; Chen Y; Ge D; Lu C
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33003204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
    Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
    Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.
    Yang S; Li K; Zhang J; Liu J; Liu L; Tan Y; Xu C
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2273-2288. PubMed ID: 38166412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 6. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
    Ye W; Huang T
    PLoS One; 2022; 17(2):e0264384. PubMed ID: 35196365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
    Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
    Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
    Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
    Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
    Ke J; Cui J; Yang X; Du X; Ma B; Yu L
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
    Shen Y; Wang S; Wu Y
    Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-methyladenosine (m6A) regulator expression pattern correlates with the immune landscape in lung adenocarcinoma.
    Wan RJ; Bai L; Jiang J; Hu CP; Chen Q; Zhao BR; Zhang Y; Li YY
    Gene; 2022 Aug; 836():146639. PubMed ID: 35700805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Liao K; Hu J; Huang Y; Yu S; Yang Q; Sun F; Wu C; Cheng Y; Zhang W; Zhang X; Li H; Wang X
    Front Oncol; 2022; 12():879405. PubMed ID: 35875124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
    Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
    Front Oncol; 2021; 11():714267. PubMed ID: 34604051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
    Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
    Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma.
    Sun J; Ping Y; Huang J; Zeng B; Ji P; Li D
    Front Cell Dev Biol; 2021; 9():705962. PubMed ID: 34422827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
    Xu H; Yin L; Xu Q; Xiang J; Xu R
    Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.